BG
The startup develops synthetic gene transfer technology that enhances the delivery of therapeutic genes to target cells within affected organs or tissues. This approach addresses the challenge of limited cellular uptake in traditional gene therapies, enabling the advancement of effective gene therapies and vaccines for disease treatment.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops synthetic gene transfer technology that enhances the delivery of therapeutic genes to target cells within affected organs or tissues. This approach addresses the challenge of limited cellular uptake in traditional gene therapies, enabling the advancement of effective gene therapies and vaccines for disease treatment.